Osaka, Japan

Mado Nakajima

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Toyonaka, JP (2014)
  • Osaka, JP (2015)

Company Filing History:


Years Active: 2014-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mado Nakajima: Innovator in Pharmaceutical Chemistry

Introduction

Mado Nakajima is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit endothelial lipase. His work has led to the filing of multiple patents, showcasing his innovative approach to drug development.

Latest Patents

Mado Nakajima holds 2 patents. His latest patents include an acetic acid amide derivative that exhibits inhibitory activity on endothelial lipase. This compound is useful as an endothelial lipase inhibitor and is part of a pharmaceutical composition that includes its pharmaceutically acceptable salt or a solvate thereof. Another significant patent involves an oxadiazole derivative that also has endothelial lipase inhibitory activity, further demonstrating his expertise in creating effective pharmaceutical compounds.

Career Highlights

Mado Nakajima is currently employed at Shionogi & Company Limited, where he continues to advance his research in pharmaceutical innovations. His work is characterized by a commitment to developing new therapeutic agents that can improve health outcomes.

Collaborations

Mado collaborates with esteemed colleagues, including Koji Masuda and Shiro Kida. Their combined expertise enhances the research and development efforts at Shionogi & Company Limited.

Conclusion

Mado Nakajima's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key inventor in the field. His work continues to pave the way for advancements in drug development and therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…